GlobeNewswire · Press release
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records
Event records load after the price chart.
Healthcare · Diagnostics & Research
The Quantellect read. OPK rose 4.32% in the Nov 18 session to $1.69, which is 4.5% below its 52-week high of $1.77. Short interest is 10.27% of float with a 0.41% borrow fee. Three active firms cover the stock as of Nov 19, 2026; two active firms with targets average $2.75 over 12 months. Descriptive summary of the data on this page, not a recommendation.
—
RSI (14) 53.4 (overbought above 70, oversold below 30)
—
FINRA settlement Oct 30, 2026
Price $1.69 · As of Nov 18, 2026, 3:59 PM ET
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records load after the price chart.
| Range | 6M |
|---|---|
| First close | — |
| Last close | — |
| High | — |
| Low | — |
| Volume | — |
OPK · NASDAQ · USD
Split-adjusted · volume in shares
— · Notable price movement not available
— · Options flow not available
Insufficient data · Tide session Nov 18, 2026
— · Industry comparison not available
Buy
Based on 3 active firms as of Nov 19, 2026 (365-day activity window)
As of Nov 19, 2026 across 2 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →— · Smart-money activity not available
All smart-money activity →GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.